The FDA granted accelerated approval to Nelkarmi for advanced ALK-positive non-small cell lung cancer after prior targeted therapies, based on tumor response data from the ALKOVE-1 trial.
Nelkarmi Wins Accelerated FDA Approval for ALK-Positive Lung Cancer That Progressed After Alectinib or Two Earlier Drugs
by | Nov 18, 2026 | Uncategorized | 0 comments

Recent Comments